Personalized Acromegaly Treatment Approach Yields Faster Hormonal Control: ACROFAST study
Spain: The prospective ACROFAST trial indicated that a tailored treatment protocol was more effective for managing acromegaly, also known as gigantism, than the conventional trial-and-error approach.
When a personalized approach was tailored using predictive biomarker testing, 78% of patients with acromegaly achieved hormonal control, compared to 53% of patients treated traditionally after one year, the researchers reported in The Journal of Clinical Endocrinology & Metabolism.
They found that after adjusting for age and sex, patients had more than double the likelihood of achieving hormonal control with the personalized approach (HR 2.53). Hormonal control was defined as normalized insulin-like growth factor 1 (IGF1) standard deviation scores.
Currently, acromegaly is medically treated through a trial-error approach using first-generation somatostatin receptor ligands (fgSRLs) as first-line drugs having an effectiveness of about 50%, and subsequent drugs are indicated through clinical judgment. Certain biomarkers have predictive capabilities for response to fgSRLs. Joan Gil, Endocrine Research Unit, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain, and colleagues report the results of the ACROFAST study, a clinical trial in which a protocol based on predictive biomarkers of fgSRLs was evaluated.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.